Beyond first-line failure: Rethinking care in refractory mSCLC
Industry Buzz
While expectations must be realistic and treatment decisions individualized, second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease. It remains a relevant part of comprehensive care when aligned with patient goals and overall clinical condition.
—Tingting Tan, MD, PhD
Refractory metastatic small-cell lung cancer (mSCLC)—with its aggressive nature and tendency to metastasize—remains one of oncology’s most profound challenges.[]
SCLC accounts for about 15% of all lung cancer patients, and the diagnosis is generally made well after the cancer has already spread. SCLC has a low survival rate.[][]
First-line treatments have long included chemo and radiotherapies, while newer therapy combinations include immunotherapy with chemotherapy. Although patients typically respond initially to first-line therapies, relapse often occurs. So, what comes next?
Second-line therapy: 'A light at the end of the tunnel'?
“In patients with metastatic small-cell lung cancer who are platinum-refractory or relapse within a short interval after first-line platinum-based chemotherapy, second-line treatment remains an important consideration, even though expected responses are limited,” says Tingting Tan, MD, PhD, a medical oncologist at City of Hope in Newport Beach, CA. “This setting is often underestimated because small-cell lung cancer has an aggressive natural history, and historically, there have been few effective options once the disease progresses early. As a result, both clinicians and patients may assume that additional therapy offers little value.”
That mindset might be wrong, however. Authors of a review article in Cancers (Basel) maintains that it’s high time clinicians start thinking deeply about second-line treatment as “the light at the end of the tunnel.”[]
Dr. Tan agrees. “For selected patients with adequate performance status,” he says, “second-line therapy can provide meaningful benefits, including temporary disease control, symptom palliation, and maintenance of functional status. Even modest responses can help slow rapid progression, reduce tumor-related symptoms, and preserve quality of life.”
Preserving future treatment pathways
But that's not the only reason second-line therapies deserve a rethink: “It may allow patients to remain candidates for subsequent lines of therapy or enrollment in clinical trials,” Dr. Tan explains, “which is particularly important given the ongoing development of novel agents in small-cell lung cancer.”
Such treatments include platinum rechallenge, along with topoisomerase I inhibitors and multi-agent chemotherapy. Alkylating agents are also used, as studies have shown that they may prolong survival while being better tolerated than other therapies. []
“While expectations must be realistic and treatment decisions individualized, second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease,” Dr. Tan says. “It remains a relevant part of comprehensive care when aligned with patient goals and overall clinical condition.”